All In Biotech

Drug Trial Radar · NCT02294955

Catheter Ablation Compared With Pharmacological Therapy for Atrial Fibrillation (CAPTAF Trial)

Catheter Ablation Compared With Pharmacological Therapy for Atrial Fibrillation - a Randomized Multicentre Study Comparing Atrial Fibrillation Ablation Strategy With Optimized Conventional Pharmacological Strategy After 12 Months Follow-up.

Last checked: Nov 19, 2026Latest source record: May 9, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 152 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

152

Actual

Start

May 2008

Primary completion

Sep 2018

Study completion Sep 2018

Sponsor

Lead sponsor
Uppsala University HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Swedish Heart Lung Foundation
First posted
Nov 19, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 30 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective is to compare the efficacy of 2 treatment strategies, catheter ablation of atrial fibrillation versus optimized pharmacological therapy, in patients with symptomatic atrial fibrillation. It is a randomized, prospective, controlled, open-label multicentre, parallel-group study including 116 patients. Inclusion criteria are patients aged 30-70 years with symptoms related to atrial fibrillation and who have failed or been intolerant to at least one anti-arrhythmic drug, with at least one atrial fibrillation episode documented on ECG during the previous 12 months and at least one symptomatic episode during the previous 2 months or at least 2 symptomatic episodes of persistent AF in the previous 12 months. Main exclusion criteria are patients who have tested 2 or more anti-arrhythmic drugs for rhythm control, uncontrolled hypertension, valvular disease requiring anticoagulation, planned valve surgery within 2 years, contraindication to treatment with anticoagulants, heart failure, left atrial diameter \> 60 mm, unstable angina or acute myocardial infarction within the last 3 months, cardiac revascularization procedure within the last 6 months, prior cardiac surgery or planned cardiac corrective surgery within 1 year, prior AF ablation procedure. The primary endpoint is general health-related quality of life at 12 months follow-up. The main secondary endpoints are morbidity and mortality as composite outcome, cardiovascular hospitalization, symptoms, heart failure, left atrial and ventricular function and diameters, exercise capacity, health care economics, rhythm, atrial fibrillation burden, successful versus failed treatment, safety and "cross-overs" over time. Patients will receive a cardiac monitor, implanted subcutaneously, which will monitor the heart rhythm during a two month "Run-in" period, for the definition of the basic atrial fibrillation burden. Patients will be randomly assigned to an antiarrhythmic drug (for rhythm or rate control) or to left atrial catheter ablation. Evaluation of outcome is at 12, 24, 36 and 48 months of follow-up, while health economy will be evaluated at 24 and 48 months of follow-up.. In case of documented disease progression or unacceptable toxicity, subjects will be switched to the alternative regimen. The main statistical analysis of the primary endpoint will be based on the intention-to-treat population. The trial duration is 48 months.

Conditions

  • Atrial Fibrillation
  • Quality of Life

Interventions

  • CatheterablationDevice

    Pulmonary vein isolation using either Arctic Front™ Cardiac CryoAblation or irrigated radiofrequency catheter ablation. A linear lesion, a left atrial roof line, is optional for patients with AF recurrence after a first procedure or primarily for patients with persistent AF.

  • AmiodaroneDrug

    Dosage orally 600 mg once daily for 7-10 days, and 100-200 mg once daily thereafter.

  • SotalolDrug

    Dosage orally 80-160 mg twice daily

  • FlecainideDrug

    Dosage orally 100 to 150 mg twice daily or the entire dose as slow-release formula once daily

  • PropafenoneDrug

    Dosage orally 300 mg twice daily

  • DisopyramideDrug

    Dosage orally 250-375 mg twice Daily

  • DronedaroneDrug

    Dosage orally 400 mg twice daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. quality of lifeTime frame: 12 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Carina Blomström Lundqvist

    Uppsala, Sweden

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.